SeptRx, Inc. Begins CE Mark Trial of the SeptRx(R) Intrapocket PFO Occluder (IPO)

Published: Jun 16, 2011

FREMONT, Calif.--(BUSINESS WIRE)-- SeptRx, an emerging medical device company that is developing the SeptRx® Intrapocket PFO Occluder (IPO)—a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO)—announced today that the first implants have been completed in the InterSEPT™ clinical trial at the CardioVascular Center at Sankt Katharinen Hospital, Frankfurt, under principal investigator Horst E. Sievert, M.D.

Back to news